Breast Cancer Trial, Recruiting NCT05782686 Sponsor: Hospital Universitari de Bellvitge Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT05782686
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have had breast-conserving surgery (surgery that removes the tumor but keeps most of the breast)
  • Imaging tests (such as mammogram, ultrasound, and/or MRI scan) showed only one single tumor in the breast
  • Your tissue sample (biopsy) confirmed either early-stage cancer cells (carcinoma in situ) or invasive breast cancer
  • You had a type of breast reshaping surgery (oncoplastic surgery) that did not involve moving tissue flaps from other parts of the body

Who may not be able to join:

  • Patients who are male
  • Patients who have previously had cancer in the same breast
  • Patients who had breast reshaping surgery that involved using tissue flaps from another part of the body
  • Patients whose cancer appears in more than one area or more than one region of the breast
  • Patients who are currently pregnant or breastfeeding
  • Patients whose cancer has spread to other parts of the body (Stage IV)
  • Patients who were considered suitable for a full breast removal (mastectomy)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Amparo Garcia Tejedor, MDPhD, Hospital de Bellvitge. Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Phone: 932607695

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hospital Universitari de Bellvitge
Registry
ClinicalTrials.gov
Start date
7 October 2020
Est. completion
16 June 2026

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Margin involvement; Re-interventions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov